We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 1.53% | 49.75 | 49.50 | 50.00 | 49.75 | 47.50 | 48.75 | 3,399,639 | 16:13:35 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.60 | 141.1M |
TIDMAVCT
Avacta Group PLC
04 July 2017
4 July 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at Manchester ShareSoc Growth Company Seminar
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the ShareSoc Growth Company Seminar on Tuesday 11(th) July at the Double Tree by Hilton Manchester Piccadilly Hotel, 1 Piccadilly Place, 1 Auburn Street, Manchester M1 3DG.
The evening event, which begins with registration at 17:30, provides an opportunity for investors to hear about the Company's Affimer(R) technology, its development plans and to discuss these with Alastair.
ENDS
NOTES
For further information from Avacta Group plc, please contact:
Avacta Group plc Tel: +44 (0) 844 414 Alastair Smith, Chief Executive 0452 Officer www.avacta.com Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) 207 220 Geoff Nash / Giles Rolls 0500 - Nominated Adviser www.finncap.com Tim Redfern / Alice Lane - Corporate Broking Tel: +44 (0) 203 705 WG Partners 9318 Nigel Birks / Nigel Barnes Tel: +44 (0) 203 705 David Wilson / Claes Spang 9217 www.wgpartners.co.uk Zyme Communications (Trade Tel: +44 (0)7787 502 and Regional Media) 947 Katie Odgaard katie.odgaard@zymecommunications.com FTI Consulting (Financial Tel: +44 (0) 203 727 Media and IR) 1000 Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUUAMUPMGUW
(END) Dow Jones Newswires
July 04, 2017 02:00 ET (06:00 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions